TY  - JOUR
SN  - 1471-2334
Y1  - 2017///
TI  - Diagnostic value of Pentraxin-3 in patients with sepsis and septic shock in accordance with latest sepsis-3 definitions
SP  - 1
A1  - Hamed, Sonja
A1  - Behnes, Michael
A1  - Pauly, Dominic
A1  - Lepiorz, Dominic
A1  - Barre, Max
A1  - Becher, Tobias
A1  - Lang, Siegfried
A1  - Akin, Ibrahim
A1  - Borggrefe, Martin
A1  - Bertsch, Thomas
A1  - Hoffmann, Ursula
CY  - London; Berlin; Heidelberg
EP  - 10
UR  - https://archiv.ub.uni-heidelberg.de/volltextserver/23338/
N2  - Background: Pentraxin-3 (PTX-3) is an acute-phase protein involved in inflammatory and infectious processes. This study assesses its diagnostic and prognostic value in patients with sepsis or septic shock in a medical intensive care unit (ICU).   Methods: The study includes 213 ICU patients with clinical criteria of sepsis and septic shock. 77 donors served as controls. Plasma levels of PTX-3, procalcitonin (PCT) and interleukin-6 were measured on day 1, 3 and 8.   Results: PTX-3 correlated with higher lactate levels as well as with APACHE II and SOFA scores (p = 0.0001). PTX-3 levels of patients with sepsis or septic shock were consistently significantly higher than in the control group (p ? 0.001). Plasma levels were able to discriminate sepsis and septic shock significantly on day 1, 3 and 8 (range of AUC 0.73?0.92, p = 0.0001). Uniform cut-off levels were defined at ?5 ng/ml for at least sepsis, ?9 ng/ml for septic shock (p = 0.0001).   Conclusion: PTX-3 reveals diagnostic value for sepsis and septic shock during the first week of intensive care treatment, comparable to interleukin-6 according to latest Sepsis-3 definitions.   Trial registration: NCT01535534. Registered 14.02.2012
JF  - BMC Infectious Diseases
AV  - public
IS  - 554
PB  - BioMed Central; Springer
ID  - heidok23338
VL  - 17
ER  -